2020 had an impact on nearly every industry around the world in 2021, with effects that will likely continue to ripple well into 2022 and possibly the years beyond. Arguably one of the industries that saw the largest shifts related directly to the events of 2020 were the Pharma and Biopharma sectors. From public perception to investor interest, the unprecedented events had a number of impacts on our industries. To celebrate the 40th episode of “The Weekly Bioanalysis”, Dom and John are joined by the CEO of KCAS, John Bucksath, to discuss these impacts and specifically the changes we’ve experienced here at KCAS within the last year or so, and what it means for the years to come!


To view/listen to the episode of “the Weekly Bioanalysis” click the play button below!


You can always find the latest episode of “The Weekly Bioanalysis” here,

but you can also subscribe to the podcast on Apple Podcasts or any of the major podcast distribution channels!


We would love to hear from you about questions you have from our podcast – or even feedback on how we could improve it!

Please use the form below to reach out to us.

Scroll to Top